The authors concluded that bismuth used in the eradication of Helicobacter pylori was safe and well tolerated. The only adverse event occurring significantly more often with bismuth was dark stools. This was a well-conducted review, but deficits in the trial quality may have led to an underestimation of the adverse events.
To assess the safety of bismuth salts used in Helicobacter pylori (H. pylori) eradication therapy.
Searching MEDLINE (1966 to October 2007 , EMBASE (1988 ( to October 2007 , the Cochrane Library and Current Contents were searched for relevant studies. Search terms were reported and there were no language restrictions. Additional studies were sought by manually checking the reference lists of identified studies. Digestive Disease Week, United European Gastroenterology Week and the European Helicobacter Study Group conference abstract books were handsearched (2000 to 2007).
Study selection
Studies were eligible if they were randomised controlled trials of bismuth monotherapy compared with acid suppression therapy alone, placebo, or no treatment; or bismuth could be given in combination with antibiotics or antibiotics and acid suppression therapy as part of a recognised eradication regimen compared with the same dose and duration of the co-treatment without bismuth. Accepted treatments included bismuth triple therapy (in combination with two antibiotics), quadruple therapy (two antibiotics plus acid suppression therapy), or ranitidine bismuth citrate dual (with one antibiotic) or triple (two antibiotics) therapy. Participants had to be H. Pylori positive adults (over 16 years) taking any bismuth compound for more than one day. Trials assessed bismuth toxicity using medical databases, face-to-face or telephone interviews, symptom diaries, or questionnaires.
The included trials were conducted in Europe, Asia, the USA, South America, and Australia. Twenty percent of the trials used more than one bismuth-containing regimen. The duration of therapy ranged between seven and 56 days, with a total daily dose of between 400mg and 2,100mg. The following treatments were used: ranitidine bismuth citrate, tripotassium dicitrato bismuthate, bismuth subsalicylate, bismuth subnitrate, and colloidal bismuth subcitrate. Comparison interventions included proton pump inhibitors, H 2 -receptor antagonists, antibiotics, and placebo. Mean age of participants was between 36.7 and 50.5 years and the percentage of male patients was between 32 and 78.
Two reviewers performed the searches. Titles and abstracts were screened and those judged to be potentially eligible for inclusion were assessed using pre-designed eligibility forms. In case of disagreement between the two reviewers, a third reviewer was consulted and agreement was reached by consensus.
Assessment of study quality
The quality of the studies was assessed using the following criteria: method of assessment of occurrence of adverse events (interview, diary, or questionnaire), method of randomisation, method of allocation concealment, blinding of assessor to patient allocation.
Data extraction
Two reviewers extracted the data concerning the total number of adverse events and the number of specific adverse events, using specially developed forms. The details of trial and patient characteristics were recorded. The proportion of patients reporting any adverse event and the proportion with specific adverse events were calculated. Data extraction was checked by a third reviewer. The verified data were entered into an Excel spreadsheet, which was also checked by the third reviewer.
